References
- Ananth J, Aduri K, Parameswaran S, Gunatilake S. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neuropsychiatrica 2004a; 16: 219–228
- Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004b; 65: 464–470
- Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251(Suppl 1)I/8–13
- Hall RCW, Chapman M. Neuroleptic malignant syndrome in the elderly: Diagnostic criteria, incidence, risk factors, pathophysiology, and treatment. Clin Geriatr 2006; 14: 39–46
- Otani K, Hayashi H, Suzuki A, Aoshima T. Malignant catatonia and neuroleptic malignant syndrome: Revisited. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1184–1185
- Ozen ME, Yumru M, Savas HA, Cansel N, Herken H. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry 2007; 8: 42–44